Mutant IDH1-IN-2 is a mutant Isocitrate dehydrogenase (IDH) proteins inhibitor

Ogalvibart (C-135-LS), a humanized anti-SARS-CoV-2 IgG1 type monoclonal antibody, specifically targets and binds to the spike (S) glycoprotein receptor-binding domain (RBD) of the SARS-CoV-2 virus. When combined with C144LS in a 1:1 ratio, Ogalvibart demonstrates significant preventive activity and effectively prevents the progression of COVID-19 in a rhesus monkey disease model [1].

Pirenzepine (LS 519 free base) is a selective antagonist of the M1 muscarinic acetylcholine receptor (mAChR). It effectively inhibits gastric acid secretion and reduces muscle spasm, making it a valuable compound for investigating peptic ulcers. Additionally, Pirenzepine exhibits anti-proliferative activity against cancer cells [1] [2].

Crexavibart (BMS-986413; C-144-LS), an IgG1 λ2 antibody, specifically targets the receptor-binding domain of the SARS-CoV-2 spike (S) glycoprotein [1].